Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H27NO2.ClH |
| Molecular Weight | 349.895 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC=C(C=C1OC)C(CCCC2=CC=CC=C2)N(C)C
InChI
InChIKey=SRKJRPFCSZFVAE-UHFFFAOYSA-N
InChI=1S/C20H27NO2.ClH/c1-21(2)18(12-8-11-16-9-6-5-7-10-16)17-13-14-19(22-3)20(15-17)23-4;/h5-7,9-10,13-15,18H,8,11-12H2,1-4H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H27NO2 |
| Molecular Weight | 313.4339 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Vetrabutine is a spasmolytic agent. As a musculotropic spasmolytic agent vatrabutine was reported to act directly on the smooth muscle fibers and to have no neurotropic activity. In pigs, its activity was specific to the uterine body and cervical musculature where it acted on the myometrial cells, sealing off the membrane against the passage of potassium ions, thereby increasing membrane potential and lowering tonus. Vetrabutine was of moderate acute oral toxicity. Vetributine hydrochloride has been used in human medicine as a spasmolytic agent in obstetrics.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:11:38 GMT 2025
by
admin
on
Mon Mar 31 21:11:38 GMT 2025
|
| Record UNII |
54IF66RP20
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
227-771-8
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY | |||
|
100000087897
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY | |||
|
54IF66RP20
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY | |||
|
SUB05093MIG
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY | |||
|
5974-09-4
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY | |||
|
m11438
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY | Merck Index | ||
|
C551390
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY | |||
|
DTXSID70975150
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY | |||
|
111121
Created by
admin on Mon Mar 31 21:11:38 GMT 2025 , Edited by admin on Mon Mar 31 21:11:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |